Trust and Psychedelic Moral Enhancement
Neuroethics May 25, 2022 DOI: 10.1007/s12152-022-09497-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Intervention | Psychedelics |
| Keywords | Neuroethics Appeal Facilitator Popularity Moral development Psychotherapist Epistemology Psychoanalysis |
| Citations | 10 |
| Key points | Argues that trusting relationships between facilitator and agent are likely to maximize the success of using psychedelics as adjuncts to moral development, and outlines concrete suggestions for facilitating trust to maximize benefits. |
Abstract
Abstract Moral enhancement proposals struggle to be both plausible and ethically defensible while nevertheless interestingly distinct from both cognitive enhancement as well as (mere) moral education. Brian Earp ( Royal Institute of Philosophy Supplement 83:415–439, 12) suggests that a promising middle ground lies in focusing on the (suitably qualified) use of psychedelics as adjuncts to moral development. But what would such an adjunctive use of psychedelics look like in practice? In this paper, I draw on literature from three areas where techniques for moral development have been discussed: psychotherapy (e.g., Overholser 2010; Burns 1980) education (e.g., Uhl and Lütge, 2018), and AI-assisted enhancement (e.g., Lara and Deckers, Neuroethics 13(3):275–287, 17) in order to propose more concrete ways in which to use psychedelics as adjuncts to moral development. It is shown that in each of these areas, we can see that trusting relationships (e.g., Baier 1986; Hawley 2019) between the facilitator and the agent will very plausibly maximize the success of this type of moral enhancement. Finally, I appeal to literature on informed consent for use of psychedelics (e.g., Smith and Sisti, Journal of Medical Ethics , 22; Johnson et al., The Journal of Psychopharmacology 22(6):603–20, 23) and on the therapeutic relationship in psychotherapy (e.g., Dryden and Reeves 2013; Horvath et al. 2011) to outline concrete suggestions for facilitating dimensions of trust most likely to maximize the benefits of (adjunctive) psychedelic moral enhancement. The result is a newly detailed practical proposal for how we might best facilitate moral enhancement by using drugs as adjuncts to moral development
Citations in the library
Cited by 7
- Acid liberalism: Silicon Valley's enlightened technocrats, and the legalization of psychedelics. International Journal of Drug Policy December 1, 2022
- On the social epistemology of psychedelic experience Philosophical Psychology June 27, 2024
- Psychedelics beyond medicine: Treatment, enhancement, hype, consent, and the limits of medicalization Philosophical Psychology September 8, 2025
- Psychedelics for Moral Bioenhancement in Healthy Individuals—A Violation of the Non-Maleficence Principle? Psychoactives February 6, 2025
- Responding to existential distress at the end of life: Psychedelics and psychedelic experiences and/ as medicine Neuroethics August 24, 2024
and 2 more in the library
Cites 10
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Predicting Responses to Psychedelics: A Prospective Study Frontiers in Pharmacology November 2, 2018
and 5 more in the library